[{"id":"b3a48768-ed71-493b-a904-634739217a2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03057145","created_at":"2021-01-18T15:03:26.356Z","updated_at":"2025-02-25T14:57:51.725Z","phase":"Phase 1","brief_title":"Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03057145","lead_sponsor":"Geoffrey Shapiro, MD, PhD","biomarkers":" BRCA1 • BRCA2 • RAD51 • H2AX","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • RAD51 • H2AX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 02/25/2020","primary_completion_date":" 02/25/2020","study_txt":" Completion: 06/09/2021","study_completion_date":" 06/09/2021","last_update_posted":"2021-09-02"},{"id":"f0cb7650-9cf7-4124-9324-f18c9ca76aca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03495323","created_at":"2021-01-18T17:12:40.498Z","updated_at":"2024-07-02T16:36:31.922Z","phase":"Phase 1","brief_title":"A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03495323","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PD-L1 • H2AX","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • H2AX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368) • lodapolimab (LY3300054)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/16/2018","start_date":" 05/16/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-04-15"}]